[HTML][HTML] Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK
L Claxton, B Malcolm, M Taylor, J Haig, C Leteneux - Drugs & aging, 2014 - Springer
Purpose The aim of this study was to evaluate the cost effectiveness of ranibizumab
compared with verteporfin photodynamic therapy (vPDT) or no treatment (observation) in …
compared with verteporfin photodynamic therapy (vPDT) or no treatment (observation) in …
RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia
S Wolf, VJ Balciuniene, G Laganovska, U Menchini… - Ophthalmology, 2014 - Elsevier
Objective To compare the efficacy and safety of ranibizumab 0.5 mg, guided by visual acuity
(VA) stabilization or disease activity criteria, versus verteporfin photodynamic therapy (vPDT) …
(VA) stabilization or disease activity criteria, versus verteporfin photodynamic therapy (vPDT) …
Ranibizumab treatment outcome in visual impairment due to myopic choroidal neovascularization: RADIANCE subgroup analysis based on baseline ocular …
Purpose The RADIANCE study evaluated the efficacy and safety of two different
ranibizumab 0.5 mg regimens versus verteporfin photodynamic therapy (vPDT) in patients …
ranibizumab 0.5 mg regimens versus verteporfin photodynamic therapy (vPDT) in patients …
Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia
M Rinaldi, F Semeraro, F Chiosi, A Russo… - Graefe's Archive for …, 2017 - Springer
Background To demonstrate the efficacy of intravitreal ranibizumab (IVR) in combination
with reduced-fluence photodynamic therapy (RF-PDT) in patients with choroidal …
with reduced-fluence photodynamic therapy (RF-PDT) in patients with choroidal …
Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single …
Aim To compare treatment outcomes for myopic choroidal neovascularisation (CNV)
managed with verteporfin photodynamic therapy (vPDT), intravitreal antivascular endothelial …
managed with verteporfin photodynamic therapy (vPDT), intravitreal antivascular endothelial …
Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?
B Voykov, F Gelisken, W Inhoffen, M Voelker… - Graefe's archive for …, 2010 - Springer
Abstract Background The Verteporfin in Photodynamic Therapy (VIP) Study failed to prove a
statistically significant benefit for myopic choroidal neovascularization (CNV) at the end of …
statistically significant benefit for myopic choroidal neovascularization (CNV) at the end of …
[HTML][HTML] Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized …
Y Chen, T Sharma, X Li, Y Song, Q Chang, R Lin… - Retina, 2019 - journals.lww.com
Purpose: To evaluate the efficacy and safety of 2 dosing regimens of ranibizumab 0.5 mg
versus verteporfin photodynamic therapy in Asian patients with visual impairment due to …
versus verteporfin photodynamic therapy in Asian patients with visual impairment due to …
[HTML][HTML] Meta-analysis of best corrected visual acuity after treatment for myopic choroidal neovascularisation
L Zhou, YQ Xing, T Li, Y Li, XS Song… - International Journal of …, 2014 - ncbi.nlm.nih.gov
AIM To compare the best corrected visual acuity (BCVA) between Verteporfin with
photodynamic therapy (PDT) and intravitreal anti-vascular endothelial growth factor (anti …
photodynamic therapy (PDT) and intravitreal anti-vascular endothelial growth factor (anti …
Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised …
L Dong, G Li, Z Song, X Cheng, J Bai, C Zhang - BMJ open, 2023 - bmjopen.bmj.com
Objectives To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-
VEGF) therapy for myopia choroidal neovascularisation (CNV), and to compare the efficacy …
VEGF) therapy for myopia choroidal neovascularisation (CNV), and to compare the efficacy …
Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis
E Wang, Y Chen - Retina, 2013 - journals.lww.com
Methods: The authors conducted comprehensive search in PubMed, EMBASE, Cochrane
Library, Biosis Preview, and LILACS. Included studies were categorized by study design …
Library, Biosis Preview, and LILACS. Included studies were categorized by study design …
相关搜索
- choroidal neovascularization pathologic myopia
- photodynamic therapy observation for the treatment
- choroidal neovascularization photodynamic therapy
- choroidal neovascularization ranibizumab in patients
- choroidal neovascularization treatment efficacy
- photodynamic therapy ranibizumab bevacizumab
- choroidal neovascularization meta analysis
- combination in the treatment ranibizumab bevacizumab
- photodynamic therapy pathologic myopia
- choroidal neovascularization reduced fluence
- photodynamic monotherapy combination treatment
- choroidal neovascularization triamcinolone acetonide
- photodynamic therapy reduced fluence
- choroidal neovascularization growth factor
- choroidal neovascularization photodynamic monotherapy
- choroidal neovascularization combination treatment